Anti-Human CD52 (Alemtuzumab Biosimilar)
Catalog #500005
| Cat # | Size | Price | Quantity | |
|---|---|---|---|---|
| 500005 | 1 mg | $200.00 | ||
| 500005 | 5 mg | $600.00 | ||
| 500005 | 20 mg | $1,350.00 |
Product Details
Alemtuzumab biosimilar is a humanized monoclonal antibody that selectively binds to CD52, a cell surface antigen present on B and T lymphocytes, monocytes, and other immune cells. By targeting CD52, it induces antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), leading to the depletion of lymphocytes. This action makes it effective for treating certain autoimmune diseases and hematological malignancies.
, Human CD52 Monoclonal Antibody
Specifications
| Clone | Alemtuzumab |
|---|---|
| Reactivities | Human |
| Isotype | Human IgG1 |
| Recommended Isotype Control | Human IgG1 isotype control |
| Format | Liquid |
| Formluation | PBS, pH 7.4 |
| Sterility | 0.2 µm filtered |
| Clonality | Recombinant |
| Conjugation | Unconjugated |
| Immunogen | Human CD52 |
| Host | CHO cells |
| Purity | >95% (HPLC, SDS-PAGE) |
| Endotoxin | < 1.0 EU/mg (LAL assay) |
| Grade | In vivo ready (RUO) |
| Application | Neutralization; Flow Cytometry; ELISA; WB |
| Purification | Protein A |
| Storage Conditions | 2-8 °C, Avoid freeze / thaw cycle |
| Shelf Life | 6 months |
| Regulatory Status | RUO |